Your browser doesn't support javascript.
loading
History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.
Minlikeeva, Albina N; Freudenheim, Jo L; Eng, Kevin H; Cannioto, Rikki A; Friel, Grace; Szender, J Brian; Segal, Brahm; Odunsi, Kunle; Mayor, Paul; Diergaarde, Brenda; Zsiros, Emese; Kelemen, Linda E; Köbel, Martin; Steed, Helen; deFazio, Anna; Jordan, Susan J; Fasching, Peter A; Beckmann, Matthias W; Risch, Harvey A; Rossing, Mary Anne; Doherty, Jennifer A; Chang-Claude, Jenny; Goodman, Marc T; Dörk, Thilo; Edwards, Robert; Modugno, Francesmary; Ness, Roberta B; Matsuo, Keitaro; Mizuno, Mika; Karlan, Beth Y; Goode, Ellen L; Kjær, Susanne K; Høgdall, Estrid; Schildkraut, Joellen M; Terry, Kathryn L; Cramer, Daniel W; Bandera, Elisa V; Paddock, Lisa E; Kiemeney, Lambertus A; Massuger, Leon F A G; Sutphen, Rebecca; Anton-Culver, Hoda; Ziogas, Argyrios; Menon, Usha; Gayther, Simon A; Ramus, Susan J; Gentry-Maharaj, Aleksandra; Pearce, Celeste L; Wu, Anna H; Kupryjanczyk, Jolanta.
Afiliación
  • Minlikeeva AN; Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
  • Freudenheim JL; Deparment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, New York.
  • Eng KH; Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
  • Cannioto RA; Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
  • Friel G; Independent Health, Buffalo, New York.
  • Szender JB; Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
  • Segal B; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
  • Odunsi K; Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York.
  • Mayor P; Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
  • Diergaarde B; Center of Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
  • Zsiros E; Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
  • Kelemen LE; Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
  • Köbel M; Center of Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York.
  • Steed H; Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.
  • deFazio A; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
  • Jordan SJ; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, Alberta, Canada.
  • Beckmann MW; Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Risch HA; Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
  • Rossing MA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
  • Doherty JA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
  • Chang-Claude J; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.
  • Goodman MT; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Dörk T; Department of Epidemiology, The Geisel School of Medicine at Dartmouth Medical, Hanover, New Hampshire.
  • Edwards R; Division of Cancer Epidemiology, German Cancer Research Cancer, Heidelberg, Germany.
  • Modugno F; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Ness RB; Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Matsuo K; Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Lower Saxony, Germany.
  • Mizuno M; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Karlan BY; Ovarian Cancer Center of Excellence, Women's Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
  • Goode EL; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Kjær SK; Ovarian Cancer Center of Excellence, Women's Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
  • Høgdall E; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
  • Schildkraut JM; School of Public Health, The University of Texas, Houston, Texas.
  • Terry KL; Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Cramer DW; Department of Gynecological Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
  • Bandera EV; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Paddock LE; Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota.
  • Kiemeney LA; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Massuger LFAG; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Sutphen R; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Anton-Culver H; Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Ziogas A; Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, Virginia.
  • Menon U; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.
  • Gayther SA; Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Ramus SJ; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.
  • Gentry-Maharaj A; Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Pearce CL; Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
  • Wu AH; New Jersey Department of Health and Senior Services, Trenton, New Jersey.
  • Kupryjanczyk J; School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey.
Cancer Epidemiol Biomarkers Prev ; 26(9): 1470-1473, 2017 09.
Article en En | MEDLINE | ID: mdl-28864456
ABSTRACT

Background:

Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.

Methods:

Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.

Results:

None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).

Conclusions:

Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470-3. ©2017 AACR.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Asunto de la revista: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Asunto de la revista: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article